Abstract:Abstract Background Major depressive disorder (MDD), also known as depression, has become the most prevalent mood disorder today. Currently, the diagnosis remains a major challenge given the disease heterogeneity and have been made by associating signs and symptoms with other diagnostic criteria. Several treatment options are available for MDD. However, less than 35% of patients achieve remission while 60% may show some degree of resistance to treatment even when receiving antidepressant treatment according to consensus guidelines and using measurement-based care. Between difficulties associated with the management of MDD, the lack of consensus on classification, diagnosis, and treatment stands out. Because of the incomplete understanding of MDD pathogenesis, it is urgent to develop studies that can help in the elucidation of the mechanisms related to the disease and the identification of biomarkers that allow its correct classification. Thus, this work aimed to perform a meta-analysis study to identify potential molecular biomarkers from different NGS databases. Methods Datasets from seven association studies stored in the IEU Open GWAS Project Database were selected. The meta-analysis was performed using the METAL tool (https://genome.sph.umich.edu/wiki/METAL_Documentation), which combines the relevance of the p-values, sample size, and the direction of the effect size. The criteria adopted for selecting the datasets were: (1) Specification of “depression”, “major depressive disorder” or “major depression” as the only phenotype; and (2) description of allele frequency data. The threshold for results significance was defined as P-value ≤5 × 10−8. After performing the analyses, only the SNPs whose direction of effect was the same in all original studies were evaluated, considering only the set of SNPs that were not significant in the original studies. Results After performing the meta-analysis, 348 new SNPs with P-value ≤5 × 10−8 were identified and, of those, 133 SNPs were mapped next to 17 genes. None of these genes was previously associated with depression. However, the GABBR1 gene, which encodes a type B GABA receptor subunit, has been associated with alcoholism, while the SORCS3 gene has been associated with attention deficit/hyperactivity disorder and Alzheimer’s disease. Conclusions The meta-analysis findings could help elucidate genes and polymorphisms involved in MDD pathogenesis. Due to MDD heterogeneity is nearly impossible to restrict and select a single disease biomarker. It is worth noting that only the identification of genetic polymorphisms involved in MDD development cannot be the only source of potential biomarkers for MDD. Indeed, it is necessary to extend the analysis to other components, such as regulatory regions, epigenetics, metabolites, etc. However, this work provide new insights into the identification of MDD potential biomarkers that can be better investigated in association to others factors related to the disease.

Genome-wide Association Study of Monoamine Metabolite Levels in Human Cerebrospinal Fluid

Peripheral Blood Gene Expression Profiles Linked to Monoamine Metabolite Levels in Cerebrospinal Fluid

Genome-wide Association Study of NMDA Receptor Coagonists in Human Cerebrospinal Fluid and Plasma

Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits

A Joint Study of Whole Exome Sequencing and Structural MRI Analysis in Major Depressive Disorder.

[Genome-wide association study with memory measures as a quantitative trait locus for schizophrenia].

The genetics of schizophrenia: glutamate not dopamine?

A Common Variant in ERBB4 Regulates GABA Concentrations in Human Cerebrospinal Fluid

Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations

Assessing the Causal Effects of Human Serum Metabolites on 5 Major Psychiatric Disorders

Multivariate GWAS of Alzheimer's disease CSF biomarker profiles implies GRIN2D in synaptic functioning

Cerebrospinal and Brain Proteins Implicated in Neuropsychiatric and Risk Factor Traits: Evidence from Mendelian Randomization

Convergence of Evidence from a Methylome-Wide CpG-SNP Association Study and GWAS of Major Depressive Disorder

A Genome-Wide Association Study of Α-Synuclein Levels in Cerebrospinal Fluid

Enrichment of Cis -Regulatory Gene Expression SNPs and Methylation Quantitative Trait Loci among Bipolar Disorder Susceptibility Variants

Revealing Potential Drug Targets in Schizophrenia Through Proteome-Wide Mendelian Randomization Genetic Insights

Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer's disease

Associations between antagonistic SNPs for neuropsychiatric disorders and human brain structure

Epigenome-wide Meta-Analysis of Blood DNA Methylation and Its Association with Subcortical Volumes: Findings from the ENIGMA Epigenetics Working Group

Mediation-adjusted multivariable Mendelian randomisation study identified novel metabolites related to mental health

B-264 Identification of Potential Biomarkers Related to Major Depressive Disorder Using a Meta-Analysis Approach